APSR2026-1083

Yes
Late-Breaking
Submitted
Poster Presentation
 
AP11-031
P73
 
Format: PPTX Only
https://storage.unitedwebnetwork.com/files/1285/1243387-46904-LOGOS_APSR26 Poster_PRO_Final_436469.pdf
Format: PDF Only
09. Asthma
15

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

Huaqiong Huang * Key Laboratory of Respiratory Disease of Zhejiang Province, The Second Affiliated Hospital of Zhejiang University School of Medicine Department of Respiratory and Critical Care Medicine Hangzhou China
Mehul Patel - AstraZeneca Respiratory, BioPharmaceuticals R&D Cambridge United Kingdom
Teodora Trasieva - AstraZeneca Respiratory and Immunology, Biometrics, BioPharmaceuticals R&D Gothenburg Sweden
Charlotta Movitz - AstraZeneca Respiratory and Immunology, Biometrics, BioPharmaceuticals R&D Gothenburg Sweden
Jonathan Marshall - AstraZeneca BioPharmaceuticals Medical Cambridge United Kingdom
Li Zhao - Shengjing Hospital of China Medical University Department of Pulmonary and Critical Care Medicine Shenyang China
Zhen Ding - Hefei First People’s Hospital Department of Pulmonary and Critical Care Medicine Hefei China
Hong Zhang - Gansu Provincial Hospital Asthma Center Lanzhou China
Dong Zhang - The First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Technology Department of Pulmonary and Critical Care Medicine Baotou China
Gang Chen - The Third Hospital of Hebei Medical University Department of Pulmonary and Critical Care Medicine Shijiazhuang China
Shuanying Yang - The Second Affiliated Hospital of Xi’an Jiaotong University Department of Pulmonary and Critical Care Medicine Xi’an China
Lijun Chen - The First People’s Hospital of Yinchuan Department of Pulmonary and Critical Care Medicine Yinchuan China
Limin Zhao - Henan Provincial People’s Hospital Department of Pulmonary and Critical Care Medicine Zhengzhou China
Dan Zhu - Jinhua Municipal Central Hospital Department of Pulmonary and Critical Care Medicine Jinhua China
Changqing Lin - Huizhou Central People's Hospital Department of Pulmonary and Critical Care Medicine Huizhou China
Presenting Author Details
Huaqiong
Huang
zr_hhq@zju.edu.cn
+8615005818703
41-50
China
Original Research
Budesonide-glycopyrronium-formoterol fumarate dihydrate onset of action and effects on patient-reported outcomes in uncontrolled asthma: findings from the China subgroup of the LOGOS study
Maximum 25 words
Abstract Content
LOGOS (NCT04609904), a randomised double-blind, double-dummy, phase 3 study, evaluated budesonide-glycopyrronium-formoterol fumarate dihydrate (BGF) in uncontrolled asthma. We assessed its onset of action and effects on patient-reported outcomes in the China subgroup.
Patients (12–80 years) with uncontrolled asthma despite medium-/high-dose ICS–LABA were enrolled and randomised to BGF 320/28.8/10 μg (BGF 28.8), BGF 320/14.4/10 μg (BGF 14.4), budesonide-formoterol fumarate dihydrate (BFF) 320/10 μg via co-suspension technology (BFFA) or BFF 320/9 μg in current suspension formulation (BFFS), twice daily for 24–52 weeks. Secondary endpoints included change from baseline in FEV1 at 5 min post-dose on Day 1 and patient-reported outcomes by percentage of responders for ACQ-5 and ACQ-7 (≥0.5-unit decrease from baseline), AQLQ+12 (≥0.5-unit increase from baseline), and SGRQ (≥4.0-unit decrease from baseline).
794 patients were randomised in China subgroup (BGF 28.8: n=210; BGF 14.4: n=156; BFFA: n=214; BFFS: n=214). Fast onset of action was observed across all groups, with changes from baseline in FEV1 at 5 min post-dose on Day 1 all nominally significantly higher than 100 mL; change in BGF 28.8 group (166 mL [95% CI: 143–189]) was numerically greater than that in BFFS group (132 mL [111–153]) and in BFFA group (126 mL [105–146]) (Table 1). Over 24 weeks, high percentages of responders were observed across all groups for ACQ-7 (BGF 28.8: 64.1%; BGF 14.4: 62.8%; BFFA: 60.7%; BFFS: 54.9%), ACQ-5 (BGF 28.8: 70.8%; BGF 14.4: 75.0%; BFFA: 73.8%; BFFS: 64.3%), AQLQ+12 (BGF 28.8: 49.8%; BGF 14.4: 54.8%; BFFA: 51.9%; BFFS: 45.0%), and SGRQ (BGF 28.8: 71.3%; BGF 14.4: 76.8%; BFFA: 68.1%; BFFS: 72.7%) (Table 1).
Consistent with findings in the global population, BGF 28.8 showed favourable patient-reported outcomes and fast onset of action among Chinese population. This fast onset was likely primarily driven by formoterol, with potential extra benefit from glycopyrronium.
 
 
 
 
 
No
Yes
https://storage.unitedwebnetwork.com/files/1285/1243387-37089-PROtable_400638.png
JPG or JPEG or PNG format ONLY
budesonide/glycopyrronium/formoterol, onset of action, Chinese population
maximum 3 keywords and no abbreviations, separated by commas
The authors would like to thank all researchers and patients involved in the study across all research centers. The authors acknowledge the late Professor Huahao Shen for his important contributions to the study design and conduct. The authors acknowledge Bingyu Bai, from Costello Medical, Singapore, for medical writing and editorial assistance, funded by AstraZeneca, which were in accordance with the Good Publication Practice (GPP) Guidelines for Company-Sponsored Biomedical Research.
347